Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$198.00 USD

198.00
549,647

-0.86 (-0.43%)

Updated Aug 8, 2025 10:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental

    Mark Vickery headshot

    Top Analyst Reports for ExxonMobil, Disney & AbbVie

    by Mark Vickery

    Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil (XOM), Disney (DIS), and AbbVie (ABBV).

      Zacks Equity Research

      AbbVie (ABBV) Stock Moves 0.47%: What You Should Know

      by Zacks Equity Research

      AbbVie (ABBV) closed the most recent trading day at $94.60, moving +0.47% from the previous trading session.

        Zacks Equity Research

        Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs

        by Zacks Equity Research

        FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K

          Zacks Equity Research

          Gilead (GILD) to Launch Generics for Leading HCV Treatments

          by Zacks Equity Research

          Given the persistent decline in HCV sales, Gilead (GILD) plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments, Epclusa and Harvoni.

            Zacks Equity Research

            AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU

            by Zacks Equity Research

            The CHMP gives positive opinion for combination use of AbbVie's (ABBV) Venclexta and Roche's Rituxan for relapsed/refractory CLL in patients who have received at least one prior therapy.

              Zacks Equity Research

              AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

              by Zacks Equity Research

              In the latest trading session, AbbVie (ABBV) closed at $92.05, marking a -0.51% move from the previous day.

                Zacks Equity Research

                Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status

                by Zacks Equity Research

                Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.

                  Zacks Equity Research

                  Company News For Sep 20, 2018

                  by Zacks Equity Research

                  Companies In The News are: TLRY,FB,CPRT,ABBV

                    Zacks Equity Research

                    Bristol-Myers' MM Drug Empliciti Application Validated by EMA

                    by Zacks Equity Research

                    Bristol-Myers' (BMY) application for multiple myeloma drug, Empliciti gets validated in Europe.

                      Zacks Equity Research

                      AbbVie Faces California Insurance Department Suit for Humira

                      by Zacks Equity Research

                      AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.

                        Zacks Equity Research

                        Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

                        by Zacks Equity Research

                        Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

                          Zacks Equity Research

                          The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder

                          by Zacks Equity Research

                          The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder

                            Zacks Equity Research

                            Pharma/Biotech Stocks to Watch This Prostate Cancer Month

                            by Zacks Equity Research

                            Here we highlight a few companies that are focused on developing treatments for prostate cancer.

                              Zacks Equity Research

                              Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

                              by Zacks Equity Research

                              Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.

                                Mark Vickery headshot

                                Top Stock Reports for JPMorgan, Mastercard & AbbVie

                                by Mark Vickery

                                Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Mastercard (MA) and AbbVie (ABBV).

                                  Zacks Equity Research

                                  Should Value Investors Consider AbbVie (ABBV) Stock Now?

                                  by Zacks Equity Research

                                  Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                                    Zacks Equity Research

                                    AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia

                                    by Zacks Equity Research

                                    AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.

                                      Zacks Equity Research

                                      Vertex Completes Enrollment in Triple Combination Studies

                                      by Zacks Equity Research

                                      Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.

                                        Kinjel Shah headshot

                                        Lilly, Teva, Pfizer & Others Await FDA Decisions in September

                                        by Kinjel Shah

                                        FDA grants approval to 34 new treatments this year so far.

                                          Zacks Equity Research

                                          Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status

                                          by Zacks Equity Research

                                          Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.

                                            Zacks Equity Research

                                            Vertex Inks Reimbursement Agreement for Orkambi in Australia

                                            by Zacks Equity Research

                                            Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.

                                              Zacks Equity Research

                                              Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus

                                              by Zacks Equity Research

                                              Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.

                                                Kinjel Shah headshot

                                                4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline

                                                by Kinjel Shah

                                                We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

                                                  Zacks Equity Research

                                                  AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

                                                  by Zacks Equity Research

                                                  AbbVie (ABBV) closed at $97.30 in the latest trading session, marking a -0.84% move from the prior day.